Intestinal Fatty Acid Binding Protein (I-FABP) As a Prognostic Marker in Critically Ill COVID-19 Patients

Overview

Journal Pathogens

Date 2022 Dec 23

PMID 36558860

Authors

Maciej Tyszko

Malgorzata Lipinska-Gediga

Anna Lemanska-Perek

Katarzyna Kobylinska

Waldemar Gozdzik

Barbara Adamik

Affiliations

Soon will be listed here.

Abstract

Gastrointestinal symptoms are common in critically ill COVID-19 patients. There is currently no generally recognized method of assessing gastrointestinal injury in unconscious or sedated intensive care unit (ICU) patients. I-FABP (intestinal fatty acid binding protein) and citrulline have previously been studied as potential biomarkers of enterocyte damage in various gastrointestinal tract diseases, and changes in the levels of these markers may reflect intestinal wall damage in COVID-19. Patients with critical COVID-19, with diagnosed sepsis, or septic shock requiring ICU treatment were included in the study. Blood samples for citrulline and I-FABP were taken daily from day 1 to 5. I-FABP levels were significantly higher in patients who eventually died from COVID-19 than in survivors, and the optimal I-FABP cut-off point for predicting 28-day mortality was 668.57 pg/mL (sensitivity 0.739, specificity 0.765). Plasma levels of I-FABP, but not citrulline, were associated with significantly higher mortality and appeared to be a predictor of poor outcome in multivariate logistic regression analysis. In conclusion, I-FABP seems to be an effective prognostic marker in critically ill COVID-19 patients. Assessing mortality risk based on intestinal markers may be helpful in making clinical decisions regarding the management of intestinal injury, imaging diagnostics, and potential surgical interventions.

Citing Articles

Intestinal Microbiota Dysbiosis Role and Bacterial Translocation as a Factor for Septic Risk.

Charitos I, Scacco S, Cotoia A, Castellaneta F, Castellana G, Pasqualotto F Int J Mol Sci. 2025; 26(5).

PMID: 40076650 PMC: 11900423. DOI: 10.3390/ijms26052028.

The Role of I-FABP, REG3α, sCD14-ST, and LBP as Indicators of GI Tract Injury in MODS Patients.

Turgunov Y, Ogizbayeva A, Assamidanova S, Matyushko D, Mugazov M, Amanova D Diagnostics (Basel). 2025; 15(5).

PMID: 40075763 PMC: 11898716. DOI: 10.3390/diagnostics15050515.

Peripheral Blood Levels of IL-27, IFABP, and DAO at Early Onset as Predictors of 28-Day Mortality in Enterogenic Sepsis Patients: A Single-Center, Prospective Pilot Study.

Ni Y, Sun R, Hu B, Liu J, Yang X, Wang J Infect Drug Resist. 2024; 17:5439-5449.

PMID: 39664725 PMC: 11633307. DOI: 10.2147/IDR.S496918.

Intraduodenal fecal microbiota transplantation ameliorates gut atrophy and cholestasis in a novel parenteral nutrition piglet model.

Manithody C, Denton C, Mehta S, Carter J, Kurashima K, Bagwe A Am J Physiol Gastrointest Liver Physiol. 2024; 327(5):G640-G654.

PMID: 39163019 PMC: 11559648. DOI: 10.1152/ajpgi.00012.2024.

Citrulline, Intestinal Fatty Acid-Binding Protein and the Acute Gastrointestinal Injury Score as Predictors of Gastrointestinal Failure in Patients with Sepsis and Septic Shock.

Tyszko M, Lemanska-Perek A, Smiechowicz J, Tomaszewska P, Biecek P, Gozdzik W Nutrients. 2023; 15(9).

PMID: 37432225 PMC: 10180779. DOI: 10.3390/nu15092100.

References

Tang W, Li D, Hazen S . Dietary metabolism, the gut microbiome, and heart failure. Nat Rev Cardiol. 2018; 16(3):137-154. PMC: 6377322. DOI: 10.1038/s41569-018-0108-7. View

Parasa S, Desai M, Chandrasekar V, Patel H, Kennedy K, Roesch T . Prevalence of Gastrointestinal Symptoms and Fecal Viral Shedding in Patients With Coronavirus Disease 2019: A Systematic Review and Meta-analysis. JAMA Netw Open. 2020; 3(6):e2011335. PMC: 7290409. DOI: 10.1001/jamanetworkopen.2020.11335. View

Sekino M, Funaoka H, Sato S, Okada K, Inoue H, Yano R . Intestinal fatty acid-binding protein level as a predictor of 28-day mortality and bowel ischemia in patients with septic shock: A preliminary study. J Crit Care. 2017; 42:92-100. DOI: 10.1016/j.jcrc.2017.07.012. View

Tarragon B, Valdenebro M, Serrano M, Maroto A, Llopez-Carratala M, Ramos A . Acute kidney failure in patients admitted due to COVID-19. Nefrologia (Engl Ed). 2022; 41(1):34-40. PMC: 7901279. DOI: 10.1016/j.nefroe.2021.02.006. View

Voth M, Duchene M, Auner B, Lustenberger T, Relja B, Marzi I . I-FABP is a Novel Marker for the Detection of Intestinal Injury in Severely Injured Trauma Patients. World J Surg. 2017; 41(12):3120-3127. DOI: 10.1007/s00268-017-4124-2. View

Camilleri M . Leaky gut: mechanisms, measurement and clinical implications in humans. Gut. 2019; 68(8):1516-1526. PMC: 6790068. DOI: 10.1136/gutjnl-2019-318427. View

Liu R, Paz M, Siraj L, Boyd T, Salamone S, Lite T . Feeding intolerance in critically ill patients with COVID-19. Clin Nutr. 2021; 41(12):3069-3076. PMC: 8007186. DOI: 10.1016/j.clnu.2021.03.033. View

Adriaanse M, Tack G, Passos V, Damoiseaux J, Schreurs M, van Wijck K . Serum I-FABP as marker for enterocyte damage in coeliac disease and its relation to villous atrophy and circulating autoantibodies. Aliment Pharmacol Ther. 2013; 37(4):482-90. DOI: 10.1111/apt.12194. View

Gu J, Han B, Wang J . COVID-19: Gastrointestinal Manifestations and Potential Fecal-Oral Transmission. Gastroenterology. 2020; 158(6):1518-1519. PMC: 7130192. DOI: 10.1053/j.gastro.2020.02.054. View

10.

Pelsers M, Hermens W, Glatz J . Fatty acid-binding proteins as plasma markers of tissue injury. Clin Chim Acta. 2005; 352(1-2):15-35. DOI: 10.1016/j.cccn.2004.09.001. View

11.

Piton G, Belon F, Cypriani B, Regnard J, Puyraveau M, Manzon C . Enterocyte damage in critically ill patients is associated with shock condition and 28-day mortality. Crit Care Med. 2013; 41(9):2169-76. DOI: 10.1097/CCM.0b013e31828c26b5. View

12.

Zhou P, Yang X, Wang X, Hu B, Zhang L, Zhang W . A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798):270-273. PMC: 7095418. DOI: 10.1038/s41586-020-2012-7. View

13.

Dickson R, Singer B, Newstead M, Falkowski N, Erb-Downward J, Standiford T . Enrichment of the lung microbiome with gut bacteria in sepsis and the acute respiratory distress syndrome. Nat Microbiol. 2016; 1(10):16113. PMC: 5076472. DOI: 10.1038/nmicrobiol.2016.113. View

14.

Boraschi P, Giugliano L, Mercogliano G, Donati F, Romano S, Neri E . Abdominal and gastrointestinal manifestations in COVID-19 patients: Is imaging useful?. World J Gastroenterol. 2021; 27(26):4143-4159. PMC: 8311532. DOI: 10.3748/wjg.v27.i26.4143. View

15.

Italia L, Tomasoni D, Bisegna S, Pancaldi E, Stretti L, Adamo M . COVID-19 and Heart Failure: From Epidemiology During the Pandemic to Myocardial Injury, Myocarditis, and Heart Failure Sequelae. Front Cardiovasc Med. 2021; 8:713560. PMC: 8382715. DOI: 10.3389/fcvm.2021.713560. View

16.

Alhazzani W, Moller M, Arabi Y, Loeb M, Gong M, Fan E . Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). Intensive Care Med. 2020; 46(5):854-887. PMC: 7101866. DOI: 10.1007/s00134-020-06022-5. View

17.

Saia R, Giusti H, Luis-Silva F, Pedroso K, Auxiliadora-Martins M, Morejon K . Clinical investigation of intestinal fatty acid-binding protein (I-FABP) as a biomarker of SARS-CoV-2 infection. Int J Infect Dis. 2021; 113:82-86. PMC: 8479553. DOI: 10.1016/j.ijid.2021.09.051. View

18.

Reintam Blaser A, Preiser J, Fruhwald S, Wilmer A, Wernerman J, Benstoem C . Gastrointestinal dysfunction in the critically ill: a systematic scoping review and research agenda proposed by the Section of Metabolism, Endocrinology and Nutrition of the European Society of Intensive Care Medicine. Crit Care. 2020; 24(1):224. PMC: 7226709. DOI: 10.1186/s13054-020-02889-4. View

19.

Spearman C, Aghemo A, Valenti L, Sonderup M . COVID-19 and the liver: A 2021 update. Liver Int. 2021; 41(9):1988-1998. DOI: 10.1111/liv.14984. View

20.

Harmer D, Gilbert M, Borman R, Clark K . Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzyme. FEBS Lett. 2002; 532(1-2):107-10. DOI: 10.1016/s0014-5793(02)03640-2. View